Page 1 of 2
12

2024

Davies S, Boller E, Chase J, Beaubrun A, Miller C, Jensen I. 2024. A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV plus test strategy for the diagnosis of influenza-like illnesses. J Med Econ 27(1):430–441; doi: 10.1080/13696998.2024.2313391.

View Abstract

2023

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in neurological emergencies from the perspective of a US hospital. Abstract EE579. ISPOR EU 2023.

View Abstract

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in cardiac surgery from the perspective of a US hospital. Abstract EE734. ISPOR EU 2023.

View Abstract

Gutierrez M, Wild S, Compton A, Paine E, Jensen I, Shah A. Cost consequences of using clevidipine in acute hypertension from the perspective of a US hospital. Abstract EE125. ISPOR EU 2023.

View Abstract

Bean K, Miller B, Jensen I, Howle K, Wilds A, Walz M, et al. The societal costs of metachromatic leukodystrophy (MLD) in the United States. Abstract EE547. ISPOR EU 2023.

View Abstract

Miller B, Russel-Szymczyk M, Jensen I, Shah A, Alexopoulos T, Herbert A, et al. Cost-consequence of cladribine tablets for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in the UK. Abstract EE658. ISPOR EU 2023.

View Abstract

Davies S, Boller E, Beaubrun A, Miller C, Jensen I. A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV Plus for the diagnosis of viral respiratory infections from a US health plan perspective. Abstract ID309. AMP 2023 Annual Meeting & Expo.

View Abstract

Jensen I, Srivastava K, Minshall M, Kemp R. Estimating the lifetime burden of illness in patients with bronchiolitis obliterans syndrome. Abstract EE539. ISPOR 2023.

View Abstract

2022

Jensen I, Cyr P. 2022. Early health economic models in gene and cell therapy to inform clinical trial design and optimize commercialization efforts. White Paper. PharmaLive.

Yao W, Jensen I, Claussen M, Dandurand K, Buffington B, Fuentes D, Mikhael M. 2022. Health economics of selective early rescue surfactant administration and standard surfactant administration for newborns with respiratory distress syndrome. J Pediatr Pharmacol Ther 27(8):695–702; doi:  10.5863/1551-6776-27.8.695.

View Abstract
Page 1 of 2
12